MTS Allstream Employee Receives National Award for Achievement in Business Continuity Management

Award presented at World Conference on Disaster Management in Toronto

WINNIPEG , July 9, 2012 /CNW/ - MTS Allstream, one of Canada's leading national communications solutions providers, is proud to congratulate Vito Mangialardi, MTS Allstream's Director of Business Continuity Management, for receiving the National Award for Business Continuity Management from the Canadian Centre for Emergency Preparedness. This award recognizes an individual who has demonstrated outstanding achievement and contribution to business continuity management. Business continuity professionals identify potential threats that may impact an organization and provide a framework for implementing safeguards to protect the interests of the organization and its customers.

"For the past 15 years, Vito has been working in the field of business continuity management. He is the founding member of MTS Allstream's Business Continuity Management program," said Mike Strople , MTS Allstream's Chief Technology Officer. "In addition to leading the Business Continuity Program at MTS Allstream, Vito is active in the field as an executive member of the Canadian Telecom Emergency Preparedness Association. The association adopts measures to protect the telecommunications industry in the event of a major disaster. We are very fortunate to have Vito's dedication and expertise as a part of our Company."

This award follows MTS Allstream's 2009 Award of Excellence by the Disaster Recovery Institute of Canada (DRI Canada ) for the Company's excellence in business continuity management.

"Planning for and responding to emergencies is an integrated business practice and we are pleased to have one of our leaders recognized by the Canadian Centre for Emergency Preparedness," added Mr. Strople . "Reliable telecommunication services are important to all of our customers. Our business continuity and emergency management program is one important element in ensuring the performance, reliability and recoverability of our services."

The Canadian Centre for Emergency Preparedness is a federally incorporated, not-for-profit organization that assists communities, governments and private business to prepare for, prevent, respond to and recover from man-made or natural disasters.

The award was given to Mr. Mangialardi recently at the World Conference on Disaster Management in Toronto . The conference gathers experts in the fields of emergency management and response, IT disaster recovery, business continuity, and risk management.

Manitoba Telecom Services Inc. (MTS Allstream)

MTS Allstream is one of Canada's leading national communication solutions companies, providing innovative communications for the way Canadians live and work today. The Company has more than 100 years of experience, with 5,500 employees across Canada . MTS Allstream's business is dynamic and consists of two operating divisions. In Manitoba, MTS is the leading full-service telecommunications provider for residential and business customers. MTS's suite of services include the latest in wireless technology, broadband services, IPTV, voice services, home security and an extensive range of business solutions. Across Canada , Allstream is a leader in IP communications and is the only national provider that focuses exclusively on the business telecommunications market. MTS Allstream has nearly two million customer connections spanning business customers across Canada and residential consumers throughout the province of Manitoba. The Company's extensive national fibre optic network spans more than 30,000 kilometres. MTS Allstream has spent 11 consecutive years on the Jantzi Social Index for leadership in social responsibility and is the recipient of the 2011 Governance Gavel Award from the Canadian Coalition for Good Governance, recognizing clear and effective public disclosure and leading governance practices. MTS Allstream's common shares are listed on the TSX (trading symbol: MBT). Customers, stakeholders and investors who want to learn more about MTS Allstream are encouraged to visit: www.mtsallstream.com. For more information about MTS's products and services, please visit www.mts.ca. For more information about Allstream's products and services, please visit www.allstream.com.

Forward-looking Statements Disclaimer

This news release includes forward-looking statements and information (collectively, the "statements") about the Company's corporate direction, business opportunities, operations, financial objectives and future financial results and performance that are subject to risks, uncertainties and assumptions. As a consequence, actual results in the future may differ materially from any conclusion, forecast or projection in such forward-looking statements. Therefore, forward-looking statements should be considered carefully and undue reliance should not be placed on them. Examples of statements that constitute forward-looking information may be identified by words such as "believe", "expect", "project", "should", "anticipate", "could", "target", "forecast", "intend", "plan", "outlook", "see", "set", "pending" and other similar terms.

Factors that could cause anticipated opportunities and actual results to differ materially include, but are not limited to, matters identified in the "Material assumptions" section below, the "Risks and uncertainties" section, elsewhere in the Company's 2011 Annual MD&A and 2011 Annual Information Form, all of which are available on SEDAR at www.sedar.com.

Please note that forward-looking statements reflect Management's expectations as at the date hereof. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

View the original article here

Business Management : What Is a Franchise Model?

A franchise model provides information on the steps and methods for how a business engages and how it works with customers. Discover how franchise models must be followed in agreement with franchise holders with help from a management teacher in this free video on business management and franchises.

Expert: Mark Clifton
Bio: Mark Clifton has an degree in marketing management from Oxford Brookes University, and has successfully completed the CELTA teacher training program of Cambridge University.
Filmmaker: Paul Volniansky

View the original article here

Online Business | Online Business Management

http://www.takeyourinfo.com/entrepreneur -- Covering general and detailed information on online business. Our online business video will help you maximize the effectiveness of your search.

View the original article here

Business Management : What Is a Franchise Model?

A franchise model provides information on the steps and methods for how a business engages and how it works with customers. Discover how franchise models must be followed in agreement with franchise holders with help from a management teacher in this free video on business management and franchises.

Expert: Mark Clifton
Bio: Mark Clifton has an degree in marketing management from Oxford Brookes University, and has successfully completed the CELTA teacher training program of Cambridge University.
Filmmaker: Paul Volniansky

View the original article here

Rx-to-OTC Switching Strategies - New Switching Opportunities in Weight Management and Smoking Cessation, but ...

NEW YORK, April 26, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Rx-to-OTC Switching Strategies - New Switching Opportunities in Weight Management and Smoking Cessation, but Encouraging the Uptake of Self-Medication Remains a Challenge

http://www.reportlinker.com/p0845628/Rx-to-OTC-Switching-Strategies---New-Switching-Opportunities-in-Weight-Management-and-Smoking-Cessation-but-Encouraging-the-Uptake-of-Self-Medication-Remains-a-Challenge.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Over-The-Counter_Drug

Rx-to-OTC Switching Strategies - New Switching Opportunities in Weight Management and Smoking Cessation, but Encouraging the Uptake of Self-Medication Remains a Challenge

Summary

GBI Research, a leading business intelligence provider, has released its latest research "Rx-to-OTC Switching Strategies - New Switching Opportunities in Weight Management and Smoking Cessation, but Encouraging the Uptake of Self-Medication Remains a Challenge" examines the key issues influencing the global OTC market and assesses why companies switch Rx drugs to OTC, their business strategies and the potential challenges and opportunities this creates. It provides an analysis of the global OTC market and forecasts broken down by geography and therapy areas. It discusses the national and international factors which impact the OTC market and companies operating in the OTC market. The report reviews the regulatory landscape in the US, Europe and Japan and highlights recent changes in regulatory procedures and guidelines. Therapy profiles provide a detailed analysis of the leading OTC drug classes and Company profiles provide a detailed analysis of the leading OTC companies. Finally the report discusses the challenges and future opportunities in the OTC market, business strategies and future outlook.

Over-the-counter (OTC) drugs are available on the market without prescription and are widely used by consumers to treat minor ailments. Today there are over 300,000 OTC medicines and ingredients available for purchase to treat a broad range of conditions including high cholesterol, weight management, skin disorders and respiratory infections. OTC medicines are strictly regulated and a number of regulatory processes have now been established to enable new and approved products to be reviewed and approved in a clear and transparent manner.

Many large pharmaceutical companies have already made strategic investment in OTC medicines including J&J, GlaxoSmithKline, Reckitt Benckiser, Bayer Healthcare, Novartis, Sanofi, Pfizer, Merck & Co. and Proctor & Gamble, and whilst their business strategies vary, their success has been based on a combination of careful product selection and positioning, optimal distribution and aggressive marketing. The market will continue to be driven by a number of external factors, including the growing and ageing population, emerging consumers, consumer empowerment and education, unmet medical need, healthcare reform and governmental support, as well as companies actively managing their patent exposure, optimizing PLM and maximizing their advertising and marketing opportunities.

Scope

- Data and analysis on the Rx-to-OTC switch market in the top seven countries which includes the US, the UK, France, Germany, Spain, Italy and Japan,

- Market Data on geographical landscape including country wise revenues, market size and market share.

- Key drivers and restraints that have created significant impact on the market.

- Regulatory landscape including the product approval process and overview of regulatory authorities in the top seven countries.

- Competitive landscape of the Rx-to OTC Switch market, including top companies profiles. The key companies studied in this report are Johnson & Johnson, GlaxoSmithKline, Bayer Healthcare, Reckitt Benckiser, Procter & Gamble, Sanofi, Merck and Pfizer.

Reasons to buy

The report will aid business development and marketing executives strategizing their product launches -

- Build effective strategies to launch their products by identifying potential geographies.

- Exploit in-licensing and out-licensing opportunities by identifying products that might probably fill their portfolio gaps.

- Develop key strategic initiatives by studying the key strategies of top competitors.

- Develop market-entry and market expansion strategies by identifying the geographic markets poised for strong growth.

1 Table of Contents

1 Table of Contents 4

1.1 List of Tables 6

1.2 List of Figures 7

2 Introduction 8

2.1 What Defines an OTC Product? 8

2.2 Why do Companies Switch Rx Products OTC? 8

2.3 Which OTC Products are Currently Available? 8

2.4 What Geographical Markets Attract OTC Switching? 10

2.5 What Are the Potential New Areas For OTC Drug Development and Why? 12

2.6 GBI Research Report Guidance 13

3 Market Characterization and Forecasts 14

3.1 Global OTC Market by Revenues 14

3.2 Global OTC Market by Region 15

3.3 Global OTC Market - Key Players 16

3.4 Global OTC Market by Therapy 17

3.5 The European OTC Market 18

3.5.1 France 20

3.5.2 Germany 20

3.5.3 Italy 21

3.5.4 The UK 21

3.5.5 Other European Countries 22

3.5.6 European OTC Market Forecasts 23

3.6 Japanese OTC Market 24

3.6.1 Japanese OTC Market Forecasts 25

3.7 North American OTC Market 26

3.7.1 The US 27

3.7.2 Canada 28

3.7.3 Latin American Countries 28

3.7.4 North America OTC Market Forecasts 29

3.8 Trends and Conclusions 30

4 Market Drivers and Restraints 31

5 Growing and Aging Populations 32

5.1 Emerging Consumer 34

5.2 Consumer Empowerment and Education 35

5.3 Unmet Medical Need 36

5.4 Product Life-Cycle Management 39

5.5 Patent Expiration 41

5.6 Healthcare Reform and Government Support 42

5.7 Advertising 43

5.8 Trends and Conclusions 44

6 Regulatory Landscape 45

6.1 Regulation in the US 45

6.2 OTC New Drug Application (NDA) 46

6.2.1 OTC Drug Monograph 46

6.2.2 Labeling 46

6.2.3 Rx-to-OTC Switches 47

6.3 Regulations in Europe 48

6.3.1 Centralized Route for Drug Approval 48

6.3.2 Decentralized Procedure for drug approval 49

6.3.3 National Procedure for Drug Approval 50

6.3.4 Drug Classification in Europe 52

6.3.5 EU Harmonization 53

6.4 Regulations in Japan 54

6.5 Trends & Conclusions 57

7 Therapy Areas 58

7.1 Coughs, Colds and Allergies 59

7.1.1 Case Study: Claritin (Merck) 60

7.1.2 Case Study: Sudafed (J&J) 62

7.1.3 Case Study: Allegra (Sanofi) 62

7.1.4 OTC Respiratory Conclusions 62

7.2 Analgesics and Pain Management 63

7.2.1 Case Study: Nurofen (Reckitt Benckiser) 64

7.2.2 Case Study: Advil (Pfizer/Wyeth) 65

7.2.3 Case Study: Tylenol (McNeil/J&J) 66

7.2.4 OTC Pain Conclusions 66

7.3 Gastrointestinal Remedies and Indigestion 67

7.3.1 Case Study: Zantac (GlaxoSmithKline/Warner-Lambert) 68

7.3.2 Prilosec OTC (Proctor & Gamble/AstraZeneca) 69

7.3.3 Pantazol/Pantazol Control (Nycomed) 69

7.3.4 Gastrointestinal OTC Conclusions 70

7.4 Medicated Dermatological Products 70

7.4.1 Case Study: Lamisil (Novartis) 71

7.5 Trends and Conclusions 71

8 Company Analysis 72

8.1 Johnson & Johnson 73

8.1.1 OTC M&A activity 74

8.1.2 OTC Production Issues 74

8.2 GlaxoSmithKline 75

8.2.1 OTC Divestment 78

8.3 Reckitt Benckiser 79

8.3.1 OTC M&A Activity 80

8.4 Bayer Healthcare AG 81

8.4.1 Restructuring 82

8.4.2 Product Line Extensions 82

8.4.3 Expansion in Fast-Growing Regions 83

8.5 Procter & Gamble 83

8.5.1 Joint Venture 85

8.6 Novartis 85

8.7 Sanofi 88

8.7.1 New Product Launches 89

8.8 Boehringer Ingelheim GmbH 90

8.9 Merck & Co. 92

8.10 Pfizer 94

8.11 Trends & conclusions 95

9 Challenges and Opportunities in the OTC Market 96

9.1 Business Strategies 96

9.2 Model for Rx-to-OTC switching 96

9.3 Brand identity and private labeling 98

9.4 Behind-the-Counter Opportunities 99

9.5 Opportunities in the emerging markets 100

9.6 Outlook 100

10 Appendix 102

10.1 Key Definitions 102

10.2 Abbreviations (in alphabetical order) 102

10.3 Sources 103

10.4 Methodology 105

10.4.1 Primary Research 106

10.4.2 Secondary Research 106

10.4.3 Contacts Us 106

10.4.4 Disclaimer 107

1.1 List of Tables

Table 1: Rx-to OTC Switch, Examples of OTC Drug Classes 9

Table 2: RX to OTC Switch, Global, Pharma and OTC sales ($bn), 2006-2010 10

Table 3: Rx-to OTC Switch, Leading OTC Drug Classes, 2010 11

Table 4: Rx-to OTC Switch, Global, OTC and Rx-to-OTC Sales ($bn), 2006-2010 14

Table 5: Rx-to OTC Switch, Global, OTC Sales by Region ($bn), 2006-2010 15

Table 6: Rx-to OTC Switch, Global, OTC Revenues of Top 10 Companies ($bn and %), 2010 16

Table 7: Rx-to OTC Switch, Global, OTC Sales by Therapy ($bn and %), 2010 17

Table 8: Rx to OTC Switch, Europe, OTC Sales by Region ($bn), 2006-2010 18

Table 9: Rx-to OTC Switch, Europe, OTC Sales by Region and Key Countries ($bn), 2011-2015 23

Table 10: Rx-to OTC Switch, Japan, OTC Sales ($ and JPY, bn), 2006- 2010 24

Table 11: Rx-to OTC Switch, Japan, OTC Sales (JPY bn and $bn), 2011-2015 26

Table 12: Rx-to OTC Switch, North America and Latin America OTC Market ($bn), 2006-2010 26

Table 13: Rx-to OTC Switch, North America and Latin America, OTC Sales ($bn), 2011-2015 29

Table 14: Rx-to OTC Switch, Treatment Decisions for Common Ailments 36

Table 15 Rx-to OTC Switch, Potential New Indications for Self-Medication 37

Table 16: Rx-to-OTC Switches Approved by FDA (number), 2000-2010 40

Table 17: Rx-to OTC Switch, Global, Patent Expiry of Leading Pharmaceutical Brands 41

Table 18: Rx-to OTC Switch, Comparison of NDA and OTC Monograph Processes 45

Table 19: Rx-to OTC Switch, National Regulation of Drug Classes and Their Distribution in France, Germany, Italy and the UK 52

Table 20: Rx-to OTC Switch, Japan, Amendments to PAL, 2005 55

Table 21: Rx-to-OTC Switch, Respiratory OTC Drugs by Indication (Number and %), 2005-2011 60

Table 22: Rx-to OTC Switch, Leading Retailer OTC Brands to Treat Coughs, Colds and Allergies 61

Table 23 Rx-to-OTC Switch, Analgesic and Pain Management OTC Drugs by Indication (Number and %), 2005-2011 63

Table 24 Rx-to OTC Switch, Leading Retailer OTC Brands To Treat Pain 64

Table 25 Rx-to-OTC Switch, Gastrointestinal and Indigestion OTC Drugs by Indication (Number and %), 2005-2011 67

Table 26 Rx-to OTC Switch, Leading Retailer OTC Brands To Treat GI Conditions 68

Table 27 Rx-to OTC Switch, Indications for Medicated Dermatological OTC Products, 2010 70

Table 28 Rx-to OTC Switch, Leading Retailer OTC Brands To Treat Dermatological Conditions 71

Table 29 Rx-to OTC Switch, Global Leading OTC Companies, 2010 72

Table 30 Rx-to OTC Switch, Johnson & Johnson Leading OTC Products, 2010 74

Table 31 Rx-to OTC Switch, GlaxoSmithKline's Revenue by Business Segment ($m), 2010 75

Table 32: Rx-to OTC Switch, GlaxoSmithkline Leading OTC Products, 2010 77

Table 33: Rx-to OTC Switch, OTC Products Identified For Divestment By GSK, 2011 78

Table 34: Rx-to OTC Switch, Reckitt Benckiser Regional Revenues ($m), 2010 80

Table 35: Rx-to OTC Switch, Reckitt Benckiser Leading OTC Products, 2010 80

Table 36: Rx-to OTC Switch, Bayer HealthCare Revenues ($m), 2010 81

Table 37: Rx-to OTC Switch, Bayer Healthcare Leading OTC Products, 2010 82

Table 38: Rx-to OTC Switch, Proctor & Gamble Leading OTC Products, 2011 84

Table 39: Rx-to OTC Switch, Novartis HealthCare Revenues ($m), 2010 86

Table 40: Rx-to OTC Switch, Novartis Leading OTC Products, 2010 87

Table 41: Rx-to OTC Switch, Boehringer Ingelheim Leading OTC Products, 2010 91

Table 42: Rx-to OTC Switch, Merck & Co.s Leading OTC Products, 2010 92

Table 43: Rx-to OTC Switch, Pfizer's leading OTC Products, 2010 94

Table 44: Rx-to OTC Switch, Profit Margins on Private Labels vs. National Brands 98

Table 45: Rx-to OTC Switch, Examples of BTC products, 2010 99

1.2 List of Figures

Figure 1: Rx-to OTC Switch, Global, OTC Market Revenues by Region (%), 2010 10

Figure 2: Rx-to OTC Switch, Sales Growth Of The OTC Market by Region (%), 2010 11

Figure 3: Rx-to OTC Switch, Leading Pharmaceutical Company Product Switches (Number), 2001-2011 12

Figure 4: Rx-to OTC Switch, Global Rx-to-OTC Sales by Region, (%), 2010 15

Figure 5: Rx to OTC Switch, Global, OTC Sales by Company (%), 2010 16

Figure 6: Rx-to OTC Switch, Global, OTC Sales by Therapy (%), 2010 17

Figure 7: Rx-to OTC Switch, Europe, OTC Sales by Region (%), 2010 18

Figure 8: Rx-to OTC Switch, Western Europe, OTC Expenditure Per Capita ($), 2010 19

Figure 9: Rx to OTC Switch, Sales Of Non-Prescription Drugs Used for Self-Medication (%), 2010 19

Figure 10: Rx-to OTC Switch, Central and Eastern Europe, OTC Expenditure Per Capita ($), 2010 22

Figure 11: Rx-to OTC Switch, Japan, OTC Drug Market by Category (%), March 31, 2011* 25

Figure 12: Rx-to OTC Switch, North America and Latin America, Sales by Region (%), 2010 26

Figure 13: Rx-to OTC Switch, North America, OTC Sales by Category (%), 2010 27

Figure 14: Rx-to OTC Switch, Market Drivers & Restraints for OTC Growth, 2011 31

Figure 15: Rx-to OTC Switch, Population Change by Region (millions), 2010 to 2100 32

Figure 16: Rx to OTC Switch, Global, Proportion of the Population Over 60 (%), 2010, 2025, 2050 33

Figure 17: Rx-to OTC Switch, Proportion of the Population Over 60 (million), 2010–2100 34

Figure 18: Rx-to OTC Switch, Emerging Economies, New Opportunities by Consumer Income Group, 2008–2018 35

Figure 19: Rx-to OTC Switch as an Integral Part of Product Line Extension 39

Figure 20: Rx-to-OTC Switches Approved by FDA (%), 2000-2010 40

Figure 21: Rx-to OTC Switch, Schematic of the Centralized Procedure 48

Figure 22: Rx-to OTC Switch, Schematic of the Decentralized Procedure 49

Figure 23: Rx-to OTC Switch, Schematic of the National Procedure 50

Figure 24: Rx-to OTC Switch, Data Exclusivity For Rx-to-OTC Switch Cycle 51

Figure 25: Rx-to OTC Switch, Criteria to Switch a Drug from a POM to P Status in the UK 53

Figure 26: Rx-to OTC Switch, MHLW Vision OTC Medicines and Generics Will Stimulate Future Pharmaceutical Growth 56

Figure 27: Rx-to OTC Switch, Top 20 Aliments for Self-Medication 58

Figure 28: Rx-to OTC Switch, Global, OTC Sales by Category (%), 2010 59

Figure 29: Rx-to OTC Switch, Johnson & Johnson Global Revenues (%), 2010 73

Figure 30: Rx-to OTC Switch, Johnson & Johnson Consumer Healthcare Revenues (%), 2010 73

Figure 31: Rx-to OTC Switch, GlaxoSmithKline's Revenue by Business Segment (%), 2010 75

Figure 32: Rx-to OTC Switch, GlaxoSmithKline Consumer Healthcare Revenues (%), 2010 76

Figure 33: Rx-to OTC Switch, Reckitt Benckiser Revenues (%), 2010 79

Figure 34: Rx-to OTC Switch, Reckitt Benckiser Regional Revenues, 2010 (%)* 79

Figure 35: Rx-to OTC Switch, Bayer HealthCare Revenues (%), 2010 81

Figure 36: Rx-to OTC Switch, Proctor & Gamble Global Revenues (%), 2011 83

Figure 37: Rx-to OTC Switch, Proctor & Gamble Regional Revenues (%), 2011 84

Figure 38: Rx-to OTC Switch, Novartis Revenues (%), 2010 85

Figure 39: Rx-to OTC Switch, Novartis HealthCare Revenues (%), 2010 86

Figure 40: Rx-to OTC Switch, Sanofi Revenues (%), 2010 88

Figure 41: Rx-to OTC Switch, Sanofi Regional Revenues (%), 2010 88

Figure 42: Rx-to OTC Switch, Boehringer Ingelheim Revenues (%), 2010 90

Figure 43: Rx-to OTC Switch, Boehringer Ingelheim Consumer Healthcare Regional Revenues (%), 2010 91

Figure 44: Rx-to OTC Switch, Merck & Co. Revenues (%), 2010 92

Figure 45: Rx-to OTC Switch, Merck Consumer Healthcare Revenues (%), 2010 93

Figure 46: Rx-to OTC Switch, Pfizer Global Revenues (%), 2010 94

Figure 47: Rx-to OTC Switch, Number of Products Approved by Company, 2010 97

Companies mentioned

Johnson & Johnson

GlaxoSmithKline

Reckitt Benckiser

Bayer Healthcare AG

Procter & Gamble

Novartis

Sanofi

Boehringer Ingelheim GmbH

Merck & Co.

Pfizer

Trends & conclusions

To order this report:

Over-The-Counter Drug Industry: Rx-to-OTC Switching Strategies - New Switching Opportunities in Weight Management and Smoking Cessation, but Encouraging the Uptake of Self-Medication Remains a Challenge

More  Market Research Report

Check our  Industry Analysis and Insights

__________________________

Contact Nicolas: nicolasbombourg@reportlinker.com

US: (805)-652-2626

Intl: +1 805-652-2626

View the original article here

Business Management : What Is a Franchise Fee?

A franchise fee is the amount of money a person, organization or company pays to the franchise holder to support the knowledge of the system. Find out how franchise fees provide opportunities to buy into this system with help from a management teacher in this free video on business management and franchises.

Expert: Mark Clifton
Bio: Mark Clifton has an degree in marketing management from Oxford Brookes University, and has successfully completed the CELTA teacher training program of Cambridge University.
Filmmaker: Paul Volniansky

View the original article here

Rx-to-OTC Switching Strategies - New Switching Opportunities in Weight Management and Smoking Cessation, … - Yahoo Finance

NEW YORK, April 26, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Rx-to-OTC Switching Strategies - New Switching Opportunities in Weight Management and Smoking Cessation, but Encouraging the Uptake of Self-Medication Remains a Challenge

http://www.reportlinker.com/p0845628/Rx-to-OTC-Switching-Strategies---New-Switching-Opportunities-in-Weight-Management-and-Smoking-Cessation-but-Encouraging-the-Uptake-of-Self-Medication-Remains-a-Challenge.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Over-The-Counter_Drug

Rx-to-OTC Switching Strategies - New Switching Opportunities in Weight Management and Smoking Cessation, but Encouraging the Uptake of Self-Medication Remains a Challenge

Summary

GBI Research, a leading business intelligence provider, has released its latest research "Rx-to-OTC Switching Strategies - New Switching Opportunities in Weight Management and Smoking Cessation, but Encouraging the Uptake of Self-Medication Remains a Challenge" examines the key issues influencing the global OTC market and assesses why companies switch Rx drugs to OTC, their business strategies and the potential challenges and opportunities this creates. It provides an analysis of the global OTC market and forecasts broken down by geography and therapy areas. It discusses the national and international factors which impact the OTC market and companies operating in the OTC market. The report reviews the regulatory landscape in the US, Europe and Japan and highlights recent changes in regulatory procedures and guidelines. Therapy profiles provide a detailed analysis of the leading OTC drug classes and Company profiles provide a detailed analysis of the leading OTC companies. Finally the report discusses the challenges and future opportunities in the OTC market, business strategies and future outlook.

Over-the-counter (OTC) drugs are available on the market without prescription and are widely used by consumers to treat minor ailments. Today there are over 300,000 OTC medicines and ingredients available for purchase to treat a broad range of conditions including high cholesterol, weight management, skin disorders and respiratory infections. OTC medicines are strictly regulated and a number of regulatory processes have now been established to enable new and approved products to be reviewed and approved in a clear and transparent manner.

Many large pharmaceutical companies have already made strategic investment in OTC medicines including J&J, GlaxoSmithKline, Reckitt Benckiser, Bayer Healthcare, Novartis, Sanofi, Pfizer, Merck & Co. and Proctor & Gamble, and whilst their business strategies vary, their success has been based on a combination of careful product selection and positioning, optimal distribution and aggressive marketing. The market will continue to be driven by a number of external factors, including the growing and ageing population, emerging consumers, consumer empowerment and education, unmet medical need, healthcare reform and governmental support, as well as companies actively managing their patent exposure, optimizing PLM and maximizing their advertising and marketing opportunities.

Scope

- Data and analysis on the Rx-to-OTC switch market in the top seven countries which includes the US, the UK, France, Germany, Spain, Italy and Japan,

- Market Data on geographical landscape including country wise revenues, market size and market share.

- Key drivers and restraints that have created significant impact on the market.

- Regulatory landscape including the product approval process and overview of regulatory authorities in the top seven countries.

- Competitive landscape of the Rx-to OTC Switch market, including top companies profiles. The key companies studied in this report are Johnson & Johnson, GlaxoSmithKline, Bayer Healthcare, Reckitt Benckiser, Procter & Gamble, Sanofi, Merck and Pfizer.

Reasons to buy

The report will aid business development and marketing executives strategizing their product launches -

- Build effective strategies to launch their products by identifying potential geographies.

- Exploit in-licensing and out-licensing opportunities by identifying products that might probably fill their portfolio gaps.

- Develop key strategic initiatives by studying the key strategies of top competitors.

- Develop market-entry and market expansion strategies by identifying the geographic markets poised for strong growth.

1 Table of Contents

1 Table of Contents 4

1.1 List of Tables 6

1.2 List of Figures 7

2 Introduction 8

2.1 What Defines an OTC Product? 8

2.2 Why do Companies Switch Rx Products OTC? 8

2.3 Which OTC Products are Currently Available? 8

2.4 What Geographical Markets Attract OTC Switching? 10

2.5 What Are the Potential New Areas For OTC Drug Development and Why? 12

2.6 GBI Research Report Guidance 13

3 Market Characterization and Forecasts 14

3.1 Global OTC Market by Revenues 14

3.2 Global OTC Market by Region 15

3.3 Global OTC Market - Key Players 16

3.4 Global OTC Market by Therapy 17

3.5 The European OTC Market 18

3.5.1 France 20

3.5.2 Germany 20

3.5.3 Italy 21

3.5.4 The UK 21

3.5.5 Other European Countries 22

3.5.6 European OTC Market Forecasts 23

3.6 Japanese OTC Market 24

3.6.1 Japanese OTC Market Forecasts 25

3.7 North American OTC Market 26

3.7.1 The US 27

3.7.2 Canada 28

3.7.3 Latin American Countries 28

3.7.4 North America OTC Market Forecasts 29

3.8 Trends and Conclusions 30

4 Market Drivers and Restraints 31

5 Growing and Aging Populations 32

5.1 Emerging Consumer 34

5.2 Consumer Empowerment and Education 35

5.3 Unmet Medical Need 36

5.4 Product Life-Cycle Management 39

5.5 Patent Expiration 41

5.6 Healthcare Reform and Government Support 42

5.7 Advertising 43

5.8 Trends and Conclusions 44

6 Regulatory Landscape 45

6.1 Regulation in the US 45

6.2 OTC New Drug Application (NDA) 46

6.2.1 OTC Drug Monograph 46

6.2.2 Labeling 46

6.2.3 Rx-to-OTC Switches 47

6.3 Regulations in Europe 48

6.3.1 Centralized Route for Drug Approval 48

6.3.2 Decentralized Procedure for drug approval 49

6.3.3 National Procedure for Drug Approval 50

6.3.4 Drug Classification in Europe 52

6.3.5 EU Harmonization 53

6.4 Regulations in Japan 54

6.5 Trends & Conclusions 57

7 Therapy Areas 58

7.1 Coughs, Colds and Allergies 59

7.1.1 Case Study: Claritin (Merck) 60

7.1.2 Case Study: Sudafed (J&J) 62

7.1.3 Case Study: Allegra (Sanofi) 62

7.1.4 OTC Respiratory Conclusions 62

7.2 Analgesics and Pain Management 63

7.2.1 Case Study: Nurofen (Reckitt Benckiser) 64

7.2.2 Case Study: Advil (Pfizer/Wyeth) 65

7.2.3 Case Study: Tylenol (McNeil/J&J) 66

7.2.4 OTC Pain Conclusions 66

7.3 Gastrointestinal Remedies and Indigestion 67

7.3.1 Case Study: Zantac (GlaxoSmithKline/Warner-Lambert) 68

7.3.2 Prilosec OTC (Proctor & Gamble/AstraZeneca) 69

7.3.3 Pantazol/Pantazol Control (Nycomed) 69

7.3.4 Gastrointestinal OTC Conclusions 70

7.4 Medicated Dermatological Products 70

7.4.1 Case Study: Lamisil (Novartis) 71

7.5 Trends and Conclusions 71

8 Company Analysis 72

8.1 Johnson & Johnson 73

8.1.1 OTC M&A activity 74

8.1.2 OTC Production Issues 74

8.2 GlaxoSmithKline 75

8.2.1 OTC Divestment 78

8.3 Reckitt Benckiser 79

8.3.1 OTC M&A Activity 80

8.4 Bayer Healthcare AG 81

8.4.1 Restructuring 82

8.4.2 Product Line Extensions 82

8.4.3 Expansion in Fast-Growing Regions 83

8.5 Procter & Gamble 83

8.5.1 Joint Venture 85

8.6 Novartis 85

8.7 Sanofi 88

8.7.1 New Product Launches 89

8.8 Boehringer Ingelheim GmbH 90

8.9 Merck & Co. 92

8.10 Pfizer 94

8.11 Trends & conclusions 95

9 Challenges and Opportunities in the OTC Market 96

9.1 Business Strategies 96

9.2 Model for Rx-to-OTC switching 96

9.3 Brand identity and private labeling 98

9.4 Behind-the-Counter Opportunities 99

9.5 Opportunities in the emerging markets 100

9.6 Outlook 100

10 Appendix 102

10.1 Key Definitions 102

10.2 Abbreviations (in alphabetical order) 102

10.3 Sources 103

10.4 Methodology 105

10.4.1 Primary Research 106

10.4.2 Secondary Research 106

10.4.3 Contacts Us 106

10.4.4 Disclaimer 107

1.1 List of Tables

Table 1: Rx-to OTC Switch, Examples of OTC Drug Classes 9

Table 2: RX to OTC Switch, Global, Pharma and OTC sales ($bn), 2006-2010 10

Table 3: Rx-to OTC Switch, Leading OTC Drug Classes, 2010 11

Table 4: Rx-to OTC Switch, Global, OTC and Rx-to-OTC Sales ($bn), 2006-2010 14

Table 5: Rx-to OTC Switch, Global, OTC Sales by Region ($bn), 2006-2010 15

Table 6: Rx-to OTC Switch, Global, OTC Revenues of Top 10 Companies ($bn and %), 2010 16

Table 7: Rx-to OTC Switch, Global, OTC Sales by Therapy ($bn and %), 2010 17

Table 8: Rx to OTC Switch, Europe, OTC Sales by Region ($bn), 2006-2010 18

Table 9: Rx-to OTC Switch, Europe, OTC Sales by Region and Key Countries ($bn), 2011-2015 23

Table 10: Rx-to OTC Switch, Japan, OTC Sales ($ and JPY, bn), 2006- 2010 24

Table 11: Rx-to OTC Switch, Japan, OTC Sales (JPY bn and $bn), 2011-2015 26

Table 12: Rx-to OTC Switch, North America and Latin America OTC Market ($bn), 2006-2010 26

Table 13: Rx-to OTC Switch, North America and Latin America, OTC Sales ($bn), 2011-2015 29

Table 14: Rx-to OTC Switch, Treatment Decisions for Common Ailments 36

Table 15 Rx-to OTC Switch, Potential New Indications for Self-Medication 37

Table 16: Rx-to-OTC Switches Approved by FDA (number), 2000-2010 40

Table 17: Rx-to OTC Switch, Global, Patent Expiry of Leading Pharmaceutical Brands 41

Table 18: Rx-to OTC Switch, Comparison of NDA and OTC Monograph Processes 45

Table 19: Rx-to OTC Switch, National Regulation of Drug Classes and Their Distribution in France, Germany, Italy and the UK 52

Table 20: Rx-to OTC Switch, Japan, Amendments to PAL, 2005 55

Table 21: Rx-to-OTC Switch, Respiratory OTC Drugs by Indication (Number and %), 2005-2011 60

Table 22: Rx-to OTC Switch, Leading Retailer OTC Brands to Treat Coughs, Colds and Allergies 61

Table 23 Rx-to-OTC Switch, Analgesic and Pain Management OTC Drugs by Indication (Number and %), 2005-2011 63

Table 24 Rx-to OTC Switch, Leading Retailer OTC Brands To Treat Pain 64

Table 25 Rx-to-OTC Switch, Gastrointestinal and Indigestion OTC Drugs by Indication (Number and %), 2005-2011 67

Table 26 Rx-to OTC Switch, Leading Retailer OTC Brands To Treat GI Conditions 68

Table 27 Rx-to OTC Switch, Indications for Medicated Dermatological OTC Products, 2010 70

Table 28 Rx-to OTC Switch, Leading Retailer OTC Brands To Treat Dermatological Conditions 71

Table 29 Rx-to OTC Switch, Global Leading OTC Companies, 2010 72

Table 30 Rx-to OTC Switch, Johnson & Johnson Leading OTC Products, 2010 74

Table 31 Rx-to OTC Switch, GlaxoSmithKline's Revenue by Business Segment ($m), 2010 75

Table 32: Rx-to OTC Switch, GlaxoSmithkline Leading OTC Products, 2010 77

Table 33: Rx-to OTC Switch, OTC Products Identified For Divestment By GSK, 2011 78

Table 34: Rx-to OTC Switch, Reckitt Benckiser Regional Revenues ($m), 2010 80

Table 35: Rx-to OTC Switch, Reckitt Benckiser Leading OTC Products, 2010 80

Table 36: Rx-to OTC Switch, Bayer HealthCare Revenues ($m), 2010 81

Table 37: Rx-to OTC Switch, Bayer Healthcare Leading OTC Products, 2010 82

Table 38: Rx-to OTC Switch, Proctor & Gamble Leading OTC Products, 2011 84

Table 39: Rx-to OTC Switch, Novartis HealthCare Revenues ($m), 2010 86

Table 40: Rx-to OTC Switch, Novartis Leading OTC Products, 2010 87

Table 41: Rx-to OTC Switch, Boehringer Ingelheim Leading OTC Products, 2010 91

Table 42: Rx-to OTC Switch, Merck & Co.s Leading OTC Products, 2010 92

Table 43: Rx-to OTC Switch, Pfizer's leading OTC Products, 2010 94

Table 44: Rx-to OTC Switch, Profit Margins on Private Labels vs. National Brands 98

Table 45: Rx-to OTC Switch, Examples of BTC products, 2010 99

1.2 List of Figures

Figure 1: Rx-to OTC Switch, Global, OTC Market Revenues by Region (%), 2010 10

Figure 2: Rx-to OTC Switch, Sales Growth Of The OTC Market by Region (%), 2010 11

Figure 3: Rx-to OTC Switch, Leading Pharmaceutical Company Product Switches (Number), 2001-2011 12

Figure 4: Rx-to OTC Switch, Global Rx-to-OTC Sales by Region, (%), 2010 15

Figure 5: Rx to OTC Switch, Global, OTC Sales by Company (%), 2010 16

Figure 6: Rx-to OTC Switch, Global, OTC Sales by Therapy (%), 2010 17

Figure 7: Rx-to OTC Switch, Europe, OTC Sales by Region (%), 2010 18

Figure 8: Rx-to OTC Switch, Western Europe, OTC Expenditure Per Capita ($), 2010 19

Figure 9: Rx to OTC Switch, Sales Of Non-Prescription Drugs Used for Self-Medication (%), 2010 19

Figure 10: Rx-to OTC Switch, Central and Eastern Europe, OTC Expenditure Per Capita ($), 2010 22

Figure 11: Rx-to OTC Switch, Japan, OTC Drug Market by Category (%), March 31, 2011* 25

Figure 12: Rx-to OTC Switch, North America and Latin America, Sales by Region (%), 2010 26

Figure 13: Rx-to OTC Switch, North America, OTC Sales by Category (%), 2010 27

Figure 14: Rx-to OTC Switch, Market Drivers & Restraints for OTC Growth, 2011 31

Figure 15: Rx-to OTC Switch, Population Change by Region (millions), 2010 to 2100 32

Figure 16: Rx to OTC Switch, Global, Proportion of the Population Over 60 (%), 2010, 2025, 2050 33

Figure 17: Rx-to OTC Switch, Proportion of the Population Over 60 (million), 2010–2100 34

Figure 18: Rx-to OTC Switch, Emerging Economies, New Opportunities by Consumer Income Group, 2008–2018 35

Figure 19: Rx-to OTC Switch as an Integral Part of Product Line Extension 39

Figure 20: Rx-to-OTC Switches Approved by FDA (%), 2000-2010 40

Figure 21: Rx-to OTC Switch, Schematic of the Centralized Procedure 48

Figure 22: Rx-to OTC Switch, Schematic of the Decentralized Procedure 49

Figure 23: Rx-to OTC Switch, Schematic of the National Procedure 50

Figure 24: Rx-to OTC Switch, Data Exclusivity For Rx-to-OTC Switch Cycle 51

Figure 25: Rx-to OTC Switch, Criteria to Switch a Drug from a POM to P Status in the UK 53

Figure 26: Rx-to OTC Switch, MHLW Vision OTC Medicines and Generics Will Stimulate Future Pharmaceutical Growth 56

Figure 27: Rx-to OTC Switch, Top 20 Aliments for Self-Medication 58

Figure 28: Rx-to OTC Switch, Global, OTC Sales by Category (%), 2010 59

Figure 29: Rx-to OTC Switch, Johnson & Johnson Global Revenues (%), 2010 73

Figure 30: Rx-to OTC Switch, Johnson & Johnson Consumer Healthcare Revenues (%), 2010 73

Figure 31: Rx-to OTC Switch, GlaxoSmithKline's Revenue by Business Segment (%), 2010 75

Figure 32: Rx-to OTC Switch, GlaxoSmithKline Consumer Healthcare Revenues (%), 2010 76

Figure 33: Rx-to OTC Switch, Reckitt Benckiser Revenues (%), 2010 79

Figure 34: Rx-to OTC Switch, Reckitt Benckiser Regional Revenues, 2010 (%)* 79

Figure 35: Rx-to OTC Switch, Bayer HealthCare Revenues (%), 2010 81

Figure 36: Rx-to OTC Switch, Proctor & Gamble Global Revenues (%), 2011 83

Figure 37: Rx-to OTC Switch, Proctor & Gamble Regional Revenues (%), 2011 84

Figure 38: Rx-to OTC Switch, Novartis Revenues (%), 2010 85

Figure 39: Rx-to OTC Switch, Novartis HealthCare Revenues (%), 2010 86

Figure 40: Rx-to OTC Switch, Sanofi Revenues (%), 2010 88

Figure 41: Rx-to OTC Switch, Sanofi Regional Revenues (%), 2010 88

Figure 42: Rx-to OTC Switch, Boehringer Ingelheim Revenues (%), 2010 90

Figure 43: Rx-to OTC Switch, Boehringer Ingelheim Consumer Healthcare Regional Revenues (%), 2010 91

Figure 44: Rx-to OTC Switch, Merck & Co. Revenues (%), 2010 92

Figure 45: Rx-to OTC Switch, Merck Consumer Healthcare Revenues (%), 2010 93

Figure 46: Rx-to OTC Switch, Pfizer Global Revenues (%), 2010 94

Figure 47: Rx-to OTC Switch, Number of Products Approved by Company, 2010 97

Companies mentioned

Johnson & Johnson

GlaxoSmithKline

Reckitt Benckiser

Bayer Healthcare AG

Procter & Gamble

Novartis

Sanofi

Boehringer Ingelheim GmbH

Merck & Co.

Pfizer

Trends & conclusions

To order this report:

Over-The-Counter Drug Industry: Rx-to-OTC Switching Strategies - New Switching Opportunities in Weight Management and Smoking Cessation, but Encouraging the Uptake of Self-Medication Remains a Challenge

More  Market Research Report

Check our  Industry Analysis and Insights

__________________________

Contact Nicolas: nicolasbombourg@reportlinker.com

US: (805)-652-2626

Intl: +1 805-652-2626

View the original article here

Business Management : What Is a Franchise Model?

A franchise model provides information on the steps and methods for how a business engages and how it works with customers. Discover how franchise models must be followed in agreement with franchise holders with help from a management teacher in this free video on business management and franchises.

Expert: Mark Clifton
Bio: Mark Clifton has an degree in marketing management from Oxford Brookes University, and has successfully completed the CELTA teacher training program of Cambridge University.
Filmmaker: Paul Volniansky

View the original article here

Business Management : What Is a Franchise Model?

A franchise model provides information on the steps and methods for how a business engages and how it works with customers. Discover how franchise models must be followed in agreement with franchise holders with help from a management teacher in this free video on business management and franchises.

Expert: Mark Clifton
Bio: Mark Clifton has an degree in marketing management from Oxford Brookes University, and has successfully completed the CELTA teacher training program of Cambridge University.
Filmmaker: Paul Volniansky

View the original article here

Online Business | Online Business Management

http://www.takeyourinfo.com/entrepreneur -- Covering general and detailed information on online business. Our online business video will help you maximize the effectiveness of your search.

View the original article here

Business Management : What Is a Franchise Model?

A franchise model provides information on the steps and methods for how a business engages and how it works with customers. Discover how franchise models must be followed in agreement with franchise holders with help from a management teacher in this free video on business management and franchises.

Expert: Mark Clifton
Bio: Mark Clifton has an degree in marketing management from Oxford Brookes University, and has successfully completed the CELTA teacher training program of Cambridge University.
Filmmaker: Paul Volniansky

View the original article here

Management Tip of the Day: Network intensely to find a job - Reuters India

Commuters make their way in the fog across London Bridge towards the financial district of London November 23, 2011.

Credit: Reuters/Chris Helgren/Files

BOSTON | Mon Apr 2, 2012 6:58pm IST

BOSTON (Reuters) - Massive, highly deliberate outreach is the only reliable path to victory when it comes to networking as part of a job search and to find new opportunities, says Harvard Business Review.

The Management Tip of the Day offers quick, practical management tips and ideas from Harvard Business Review and HBR.org (www.hbr.org). Any opinions expressed are not endorsed by Reuters.

"The best way to find a job is through networking. But don't limit your outreach to close friends and current colleagues. Cast a wide net and reach people beyond your immediate circle.

Here are three steps to do that:

1. Broadly define your network. You have more contacts than you think. Consider former classmates, former colleagues, clients, and community acquaintances. When you make a contact, ask for introductions to others.

2. View discussions as learning opportunities. Approach meetings as conversations, not interviews. Ask about more than jobs. Ask about the industry, how to succeed, and how to position yourself.

3. Keep good records. Connecting with many people can be complicated. After each meeting, write down what you learned and what you'll do as a result."

Today's management tip was adapted from "Find a Job with Massive, Structured Networking" by Bill Barnett.

(For the full post, see: here)

View the original article here

Business Management : What Is a Franchise Model?

A franchise model provides information on the steps and methods for how a business engages and how it works with customers. Discover how franchise models must be followed in agreement with franchise holders with help from a management teacher in this free video on business management and franchises.

Expert: Mark Clifton
Bio: Mark Clifton has an degree in marketing management from Oxford Brookes University, and has successfully completed the CELTA teacher training program of Cambridge University.
Filmmaker: Paul Volniansky

View the original article here

Business Management : What Is a Franchise Model?

A franchise model provides information on the steps and methods for how a business engages and how it works with customers. Discover how franchise models must be followed in agreement with franchise holders with help from a management teacher in this free video on business management and franchises.

Expert: Mark Clifton
Bio: Mark Clifton has an degree in marketing management from Oxford Brookes University, and has successfully completed the CELTA teacher training program of Cambridge University.
Filmmaker: Paul Volniansky

View the original article here

Bluesky Selects Management Team - Consumer Electronics Net

Company News: Page (1) of 1 - 03/16/12March 16, 2012 --

CENTURY CITY, Calif., March 16, 2012 /PRNewswire/ -- Bluesky Systems Holdings, Inc. (OTCQB: BSKS.PK) ("Bluesky" "BSKS" or the "Company") announced today that the company has selected its executive management team. The team will direct all Corporate Strategy, Marketing, Operations and Business Development efforts. The team will work to secure strategic Fortune 100 corporation partnerships and commercialize a successful product line to market in multiple verticals worldwide.

"This management team has a proven track record of more than 100+ years in the intelligence, technology and information security sector, with successful commercialization and execution skills along with a history of success leveraging key relationships. With their combined experience in the technology, security, government markets, I am confident that they will bring our products to the global markets quickly," said Dan Kehoe, CEO, Bluesky.

Susan Lutz, President of the Company, heads the executive management team that she has a solid history with. "Supera not only represents an incredible venture; but the opportunistic fortune to hand select a team of individuals whom I have admired and with whom I have worked with in previous successful ventures. This is truly the opportunity of a lifetime," stated Ms. Lutz.

Suzanne Ronca will serve as Chief Marketing Officer and EVP Sales/Business Development. Ms. Ronca has held many Senior positions and has extensive experience in telecommunications, marketing, program management and sales/business development both internationally as well as domestically. Information Security and business development are her specialties. She began her career at AT&T Bell Labs and advanced into other AT&T lines of business where she developed and led teams in information security, fraud control, system architecture, marketing and program management. Upon leaving AT&T, she joined Network Associates, Inc. where she led a team responsible for the delivery of security professional services to Fortune 1000 companies. Later, at McAfee, Ms. Ronca led several team efforts for selling, implementing and marketing McAfee products into their Partner environments, driving ongoing revenue streams with some of the largest ISPs in the world. With the acquisition of McAfee by Intel, Ms. Ronca has been focusing her business development skills on synergistic areas between the companies in the consumer market.

Curtis T. Blount will serve as Chief Strategist and Security Officer. Mr. Blount has over 25 years of IT Government and Private security experience, intelligence community and a proven track record of delivering corporate security solutions and programs. Previously, Mr. Blount began his career working with the US Army as a Military Intelligence Analyst at the NATO headquarters in Europe. He then went on to GE Aerospace assigned to Cape Canaveral as a Shuttle Integration Engineer for six shuttle launches. He then entered the more specialized security field, working for the US Department of Justice where he was responsible for the 3rd Circuit Court network and security infrastructure and database application programming. He has also had the experience of working for a number of Fortune 500 companies as a Chief Security Officer in New York, including Merrill Lynch, Ogilvy and Mather Worldwide and Jones of New York.

Lauren Shippy will serve as the Business Strategy and Development Specialist. Lauren has been involved in developing business opportunities and ventures in the technology, automotive and financial industries for corporations. Her strengths include project management, market research and strategy development. She has held Business Development, Operations Management and Marketing & Sales positions in two private equity companies. Lauren has also had experience with a Family Investment Office, serving as the Chief Operating Officer, managing the team and completing due diligence on investment opportunities, including financial strategy.

In addition, the Company announced that Raleigh Waller will serve as the Company's Chief Financial Officer. Mr. Waller, seventeen years a Social/Serial Entrepreneur, draws on forty years of manufacturing, operational, accounting, and management experience to qualify and quantify market and business opportunities. Mr. Waller is a California CPA "Inactive" and holds Series 7, 4 and 66 licenses as a Registered Representative; recently with Mutual Securities. He has held positions as VP for manufacturing and engineering in the heat transfer, aerospace and EDM machining industries. Mr. Waller has been interested in secure stored value and data cards since 2008 as a technology for growing communities of interest, leading him to become an early investor in BSKS.

About Bluesky Systems Holdings, Inc.

Bluesky System Holding, Inc. (OTC:QB:BSKS) is the exclusive worldwide licensee of next generation secure data cards by reason of a certain License Agreement with Supera Group, LLC. ("Supera"). In connection with that Agreement, BSKS licensed more than 30 issued patents for the manufacture and sale of readers/writers and high-capacity data storage in a credit card format for the use in healthcare, and patient management, medical, dental and pharmaceutical records and other health applications. Bluesky expects the licensed technology to be a game changer in that the delivery of this next generation platform brings secured transactions into the modern world of technology that is being demanded by users.

FORWARD-LOOKING STATEMENTS

Statements contained herein that are not based on historical fact, as well as other statements including words such as "anticipate," "believe," "plan," "estimate," "expect," "intend," "will," "could" and other similar expressions, constitute "forward-looking statements" as that term is defined in Section 27A of the United States Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities. Actual results could differ from those projected in any forward-looking statements due to numerous factors. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in BSKS's annual report on Form 10-K for the most recent fiscal year, BSKS's quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission.

Contact Information:
- ??? Lawrence Sands
???????? Corporate Secretary
???????? Bluesky Systems Holdings, Inc.
???????? 213-412-3188

SOURCE Bluesky Systems Holdings, Inc.

Copyright 2010 PR Newswire. All Rights Reserved

Related Keywords:Computers/Peripherals, Family, Family, Prosumer/Consumer, Business, Programming, Marketing, Authoring/Programming, Storage, USA, Inc., , IT (Information Technology), Security, Financial, Internet Service Providers, Medical, Computer Science, Engineering, Business, Judicial, Military, Internet Information Provider, Family, Other,
Related Sites: CEN - Consumer Electronics Net ,   VideoBasedTutorials

Related Newsletters: CEN - Gadgets Newsletter ,   Tutorial Finder ,   Review Seeker Source:PR Newswire. All Rights Reserved

View the original article here

2012 International Impact Investing Challenge: Kellogg School of Management and Haas School of Business … - Yahoo Finance

EVANSTON, Ill., March 14, 2012 /PRNewswire/ -- Financial vehicles that deliver social and environmental impact continue to be a growing area of interest for investors. To spur interest in this emerging field, the Kellogg School of Management at Northwestern University and the Haas School of Business at the University of California, Berkeley are sponsoring the 2012 International Impact Investing Challenge. The challenge provides graduate students the opportunity to create high-performance, high-reward, high-impact investment strategies.

"Now in its second year, the International Impact Investing Challenge encourages students from graduate schools around the world to identify strategies that create solutions for global social issues – as well as deliver financial returns," said Jamie Jones, associate director of the Social Enterprise at Kellogg (SEEK) program at the Kellogg School. "Last year, student teams wowed us with their financial creativity, developing ideas to address issues like the food supply in India, clean power for First Nations, and mobile technology in emerging markets, and so we're excited to see the innovation that students will bring forth in the 2012 competition." 

Teams were invited to submit a prospectus by March 8. Ten finalist teams will present their proposals at a final event at the Federal Reserve Bank in San Francisco on April 13. The judging panel will be comprised of experienced officers and investors who currently manage family foundations, pension funds and university endowments, among others, and $15,000 in prizes will be awarded to the winning teams.

"We have a real opportunity here to elevate and showcase the intersection of finance and social impact that is a primary area of study for many Haas students," said Jo Mackness, executive director of the Center for Responsible Business (CRB) at Berkeley-Haas.

The International Impact Investing Challenge is sponsored by New World Ventures; Equilibrium Capital Group; The McCall Foundation; Forest Capital Partners LLC; Impact Assets; the Carol & Larry Levy Social Entrepreneurship Lab; the Calvert Foundation; the Milken Institute; and Water Asset Management LLC.

"We are proud to be part of a program that challenges business school students to apply their creativity and finance education to build investment strategies that deliver market returns and impact," said Dave Chen, managing principal at Equilibrium Capital Group. "These student projects show us that returns and positive impact are simply good investing."

More Info: To obtain a press pass to the event or to schedule an interview, contact Betsy Berger at b-berger@kellogg.northwestern.edu or Pamela Tom at ptom@haas.berkeley.edu. To learn more about the International Impact Investing Challenge, visit www.impactinvestingchallenge.org. For more information about the Kellogg School of Management, visit www.kellogg.northwestern.edu. For more information about the Haas School of Business at the University of California, Berkeley, visit http://www.haas.berkeley.edu/

MEDIA CONTACT:
Betsy Berger
Kellogg School of Management
Office: 847-467-3108
b-berger@kellogg.northwestern.edu

View the original article here

Research and Markets: Smart Textiles and Wearable Technology: Opportunities for Life Enhancement and Health Management ...

DUBLIN--(BUSINESS WIRE)--

Research and Markets (http://www.researchandmarkets.com/research/1c7623/smart_textiles_and) has announced the addition of Textiles Intelligence's new report "Smart Textiles and Wearable Technology: Opportunities for Life Enhancement and Health Management" to their offering.

Smart textiles and wearable technology have the potential to change the way people dress, communicate, respond to emergencies, manage their health and even entertain themselves. They could also provide a much needed boost to the textile industries in the developed world. This report provides a wealth of information including descriptions of the characteristics of smart textiles and wearable technology, the development of the industry, the materials and technologies used, projects and corporate collaborations, potential markets, and opportunities and threats in the market. It also provides an overview of the applications of smart textiles and wearable technology in a number of fields -- namely fashion, communications, entertainment and infotainment, medical and healthcare, occupational health and safety, high visibility apparel, sports, and cosmetotextiles. Furthermore, the report presents examples of innovative smart textile and wearable technology products on the market.

Key Topics Covered:

INTRODUCTION

DEFINITIONS AND CHARACTERISTICS OF SMART TEXTILES AND WEARABLE TECHNOLOGY

DEVELOPMENT OF SMART TEXTILES AND WEARABLE TECHNOLOGY

MATERIALS AND TECHNOLOGIES USED TO MAKE SMART TEXTILES AND WEARABLE TECHNOLOGY

PROJECTS AND CORPORATE COLLABORATIVE VENTURES IN SMART TEXTILES AND WEARABLE TECHNOLOGY

APPLICATIONS OF SMART TEXTILES AND WEARABLE TECHNOLOGY

THE MARKET FOR SMART TEXTILES AND WEARABLE TECHNOLOGY

OPPORTUNITIES AND THREATS IN THE MARKET

EXAMPLES OF INNOVATIVE SMART TEXTILES AND WEARABLE TECHNOLOGIES

OUTLOOK

List of tables

List of figures

Companies Mentioned:

ProeTEX

Apple

Burton Snowboards

Nike

Polar Electro

Adidas

Google

CuteCircuit

Fabrican

Freer Logic

Orange

SmartLife

Under Armour

ViewSport

WarmX

For more information visit http://www.researchandmarkets.com/research/1c7623/smart_textiles_and

View the original article here

Research and Markets: Smart Textiles and Wearable Technology: Opportunities for Life Enhancement and Health Management in 2012 - CNBC

  Data is a real-time snapshot  *Data is delayed at least 15 minutes
Global Business and Financial News, Stock Quotes, and Market Data and Analysis

© 2012 CNBC LLC.  All Rights Reserved.

View the original article here

Online Business | Online Business Management

http://www.takeyourinfo.com/entrepreneur -- Covering general and detailed information on online business. Our online business video will help you maximize the effectiveness of your search.

View the original article here

Debt Management Tips : How to Increase a Credit Score

Increasing a credit score can be done by making payments on time and keeping credit balances 30 to 40 percent of their overall limit. Enjoy a higher credit score by not closing out smaller credit cards with tips from a certified public accountant and credit counselor in this free video on debt management.

Expert: Jerrie Guthrey
Bio: Jerrie Guthrey has been a certified public accountant and credit counselor since 1992.
Filmmaker: Jack Guthrey

View the original article here